Skip to main content
Lung cancer metastasis-National Cancer Institute \ Winship Cancer Institute of Emory University

Host-Tumor Interactions Research Program

Tumor growth, invasion, and metastasis depend not only on the tumor cell alone, but also on the complex interactions between the tumor cells and their host. The goal of the Host-Tumor Interactions Research Program is to develop a detailed and mechanistic understanding of not just the tumor cell and tumor mutations, but also all the components of the host microenvironment that influence cancer and the response to cancer therapy.

RESEARCH THEMES

With the goal of understanding how complex interactions between tumor cells and their host contribute to cancer, the Host-Tumor Interactions program focuses on four specific research themes:

Understanding how new blood vessels form to feed tumors – and finding ways to block these processes

Identifying molecules involved in communication between tumor cells and their cellular and structural microenvironment

Uncovering how inflammation triggers and promotes cancer

Integrating knowledge about host-tumor interactions to understand how tumors evolve in a changing microenvironment

Meet the Program Members

The Host-Tumor Interactions program is co-led by Mary M. Zutter, M.D., and Jeffrey Rathmell, Ph.D. The basic, translational, and clinical scientists who make up this program are focused on discovering and understanding these interactions, with the ultimate goal of developing strategies to control tumor progression and metastasis by targeting these interactions.


Featured Publications

Program News

July 19, 2019

Center for Immunobiology grows, bolsters program

The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.
July 11, 2019

Vanderbilt vaccine pioneer James Crowe honored with major science prize

James Crowe Jr., MD, has been honored by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses.
June 29, 2019

Study identifies critical regulator of tumor-specific T cell differentiation

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work